Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Roivant Sciences Ltd. (Nasdaq: ROIV) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Bermuda-incorporated biopharmaceutical issuer with common shares listed on The Nasdaq Global Select Market, Roivant files annual reports, quarterly updates, current reports on Form 8-K, proxy statements and other disclosures that describe its business, governance, financial condition and material events.
Through Roivant’s filings, investors can review detailed information on its biopharmaceutical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as the activities of subsidiaries such as Priovant Therapeutics, Immunovant, Pulmovant and Genevant. Current reports on Form 8-K have been used to furnish press releases on quarterly financial results, to report positive Phase 3 VALOR data in dermatomyositis, to provide updates on Graves’ disease development at Immunovant, and to disclose authorization of common share repurchase programs.
Roivant’s periodic reports discuss consolidated research and development and general and administrative expenses, share-based compensation, gains and losses from transactions such as the sale of Telavant net assets and the sale of its equity interest in Dermavant, and income or loss from discontinued operations. The company’s definitive proxy statement on Schedule 14A describes its annual general meeting of shareholders, director elections, auditor ratification and advisory votes on executive compensation, and lays out governance and compensation policies.
On Stock Titan, Roivant filings are paired with AI-powered summaries designed to help readers interpret complex documents. Users can quickly see the key points from 10-K and 10-Q reports, understand the significance of 8-K disclosures, and locate information related to capital allocation, clinical programs and subsidiary activities. Form 4 and other ownership-related filings, when available, can be used to track insider transactions and equity incentives disclosed by the company.
Richard Pulik, Chief Financial Officer of Roivant Sciences Ltd. (ROIV), reported the disposition of 1,235 common shares on 08/20/2025 at a price of $11.72 per share, leaving him with 396,318 shares beneficially owned. The filing explains this was a net settlement of previously granted restricted stock units to satisfy tax withholding obligations upon vesting. The transaction was reported on a single-person Form 4 and executed by an attorney-in-fact.
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), reported multiple Section 16 transactions dated 08/20/2025. The filing shows a net settlement of 7,051 restricted stock units to satisfy tax withholding at a weighted average price of $11.72, a sale of 100,000 shares at a weighted average price of $11.72 effected under a Rule 10b5-1 trading plan adopted on 06/25/2024, and an award/recording of 100,000 stock options with an exercise price of $3.85. After the transactions, the reporting person’s direct common stock holdings are shown as 1,653,585 and then 1,753,585 shares at different steps; total derivative securities beneficially owned following the reported option award are reported as 8,038,897 (direct). The form includes an explanation that the RSU transfer was a net settlement for taxes and that the sales were pursuant to the 10b5-1 plan.
Roivant Sciences Ltd. (ROIV) Form 144 notifies proposed sale of 100,000 common shares to be executed on 08/20/2025 through Rockefeller Financial LLC on NASDAQ, with an aggregate market value listed as $1,172,120.12. The shares were shown as acquired by exercise of options on 08/20/2025 (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also disclosed multiple recent sales by Eric Venker totaling 1,330,148 shares between 05/20/2025 and 07/21/2025 with gross proceeds reported for each transaction.
Roivant Sciences (ROIV) disclosure shows a group of Viking Global entities and three executive committee members collectively beneficially own 34,237,779 Common Shares, representing 5.02% of the 682,229,832 shares outstanding reported by the issuer.
The filing (Schedule 13G, Amendment No. 5) lists each reporting person and the number of shares for which they have shared voting and dispositive power (VGI: 34,237,779; VGP: 18,346,865; VGEM: 17,979,927; VLFM: 6,384,710; VGOP: 9,506,204; VGEII: 366,938). The reporting persons state the securities were not acquired to change or influence control of the issuer.
QVT Financial LP reported beneficial ownership of 29,381,635 common shares of Roivant Sciences Ltd., representing 4.30% of the outstanding class. The filing is a Schedule 13G (Amendment No. 5) covering common shares (CUSIP G76279101) with the relevant event date noted as 06/30/2025. QVT reports sole voting and dispositive power over all shares disclosed. The statement is a passive ownership disclosure rather than an active solicitation filing and indicates transparency about a sub-5% stake rather than a controlling position.
Roivant Sciences Ltd. reported a quarterly net loss attributable to Roivant of $223.4 million for the three months ended June 30, 2025, compared with net income of $95.3 million in the prior-year period, driven by higher operating expenses and the absence of a prior-period sale gain.
The company held $1.24 billion in cash and cash equivalents and $3.26 billion in marketable securities at quarter-end, totaling approximately $4.50 billion in liquid assets. Total assets were $5.03 billion and total shareholders' equity was $4.82 billion. Revenue for the quarter was $2.17 million, down from $7.99 million, while research and development expense rose to $152.9 million and general and administrative expense increased to $134.0 million. Net cash used in operating activities was $204.4 million and the company completed a $1.5 billion share repurchase program, spending $208.3 million in the quarter, and authorized a new $500 million repurchase facility.
Roivant Sciences Ltd. filed a Current Report on Form 8-K stating that on August 11, 2025 the company issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.
The filing clarifies that the information in the Item 2.02 section and the attached exhibit is not deemed "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings except by express reference. The report is signed by Keyur Parekh as Authorized Signatory on August 11, 2025, and identifies the company’s Nasdaq trading symbol as ROIV.
Roivant Sciences (ROIV) Form 4, filed 1 Aug 2025, discloses a large equity grant to President & Vant Chair Frank Torti. On 30 Jul 2025 he received (i) 1,836,547 time-based RSUs that vest 20 % after one year and quarterly thereafter, and (ii) 11,900,000 performance-based PSUs split into six price-hurdle tranches ($15–$30). Each tranche vests only after both a share-price test (30-day VWAP before 26 Jul 2029) and one additional year of service, followed by a two-year holding lock-up. The award was granted at $0 cost; no open-market buying occurred.
Post-grant, Torti’s beneficial ownership rises to 13,736,547 common shares, all held directly. While the structure tightly links vesting to long-term price performance, full issuance would add material dilution if all hurdles are met.
FAQ
What is the current stock price of Roivant Sciences (ROIV)?
What is the market cap of Roivant Sciences (ROIV)?
